Eli Lilly and Company Common Stock (LLY)
Stock · NYSE · Health Care
$1,257as of 10/16/2026
Price chart
Active signals
LLY Signal Track Record
How signals performed across all stocks →What LLY's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | +3.6% | 56% | September 18, 2026 |
| Bollinger Band BreakoutActive now | 21 | +2.2% | 62% | August 19, 2026 |
| Bollinger Band Breakdown | 18 | +1.3% | 67% | April 27, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -2.7% | 36% | April 15, 2026 |
| Any 20-session window (baseline) | +1.9% | 60% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humu…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 50,000
- Website
- www.lilly.com/
Fundamentals
- 1-day range
- $1,152$1,180
- Market cap
- $1.12T
- P/E (trailing)
- 42.56
- P/E (forward)
- 24.76
- EPS (trailing)
- $29.80
- Dividend yield
- 0.75%
- Beta
- 0.42
- Avg. volume
- 2.48M
- Ex-dividend date
- August 14, 2026
- Dividend pay date
- September 10, 2026
How Eli Lilly and Company Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
29 analyst ratings
Eli Lilly and Company Common Stock Competitors
Chosen by industry and closest market cap.
- LLYEli Lilly and Company Common Stock$1,257▲ 0.43%Market cap $1.12TP/E 42.56$783.85$1,293
- JNJJohnson & Johnson Common Stock$255.56▲ 0.90%Market cap $619.30BP/E 38.77$184.66$281.07
- ABBVAbbVie Inc. Common Stock$285.42▲ 0.71%Market cap $430.95BP/E 79.39$190.75$285.4
- MRKMerck & Company Inc. Common Stock (new)$145.95▲ 0.52%Market cap $317.05BP/E 112.60$82.01$156.92
- NVSNovartis AG Common Stock$150.62▲ 0.16%Market cap $294.26BP/E 21.21$97.05$132.68
- AZNAstraZeneca PLC Ordinary Shares$165.41▼ 0.76%Market cap $249.78BP/E 24.19$11,404$15,730
- NVONovo Nordisk A/S Common Stock$38.83▼ 0.99%Market cap $203.55BP/E 9.74$224.25$409.95
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LLY Eli Lilly and Company Common Stock | $1.12T | 42.56 | $1,257 | ▲ 0.43% | $783.85$1,293 |
| JNJ Johnson & Johnson Common Stock | $619.30B | 38.77 | $255.56 | ▲ 0.90% | $184.66$281.07 |
| ABBV AbbVie Inc. Common Stock | $430.95B | 79.39 | $285.42 | ▲ 0.71% | $190.75$285.4 |
| MRK Merck & Company Inc. Common Stock (new) | $317.05B | 112.60 | $145.95 | ▲ 0.52% | $82.01$156.92 |
| NVS Novartis AG Common Stock | $294.26B | 21.21 | $150.62 | ▲ 0.16% | $97.05$132.68 |
| AZN AstraZeneca PLC Ordinary Shares | $249.78B | 24.19 | $165.41 | ▼ 0.76% | $11,404$15,730 |
| NVO Novo Nordisk A/S Common Stock | $203.55B | 9.74 | $38.83 | ▼ 0.99% | $224.25$409.95 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Veeva Systems’ (VEEV) Comeback Gets Jim Cramer TalkingYahoo · 10/10/2026
- 3 Biotech Stocks To Watch In October 2026Yahoo · 10/10/2026
- Does The Move In Merck Stock Change Anything?Yahoo · 10/9/2026
- Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow BuildsYahoo · 10/9/2026
- QYLG Vs. QDVO: Market Fear Is Good For These PaychecksSeekingAlpha · 10/9/2026
- Eli Lilly (LLY) As Zepbound And Retatrutide Updates Test Whether More Upside Is Priced InYahoo · 10/9/2026
- 10 Health Care Stocks Whale Activity In Today’s SessionBenzinga · 10/9/2026
- Eli Lilly (LLY) Posted 48% Revenue Growth. Why Does the Stock Trade Below Its Average Multiple?Yahoo · 10/9/2026
- Dow Falls Over 300 Points As Treasury Yields Surge: Investor Sentiment Weakens, Fear & Greed Index Remains In ‘Neutral’ Zonebenzinga · 10/8/2026
Insider Activity
Insider Actions →- Juan R. Luciano · September 21, 2026 · Grant14 @ $1,165
- J. Erik Fyrwald · September 21, 2026 · Grant9 @ $1,165
- Ralph Alvarez · September 21, 2026 · Grant11 @ $1,165
- Gabrielle Sulzberger · September 21, 2026 · Grant4 @ $1,165
- Melissa Seymour · September 9, 2026 · Gift12
- Eric Dozier · September 2, 2026 · Gift216
- Hernandez Edgardo · September 2, 2026 · Gift13
- Jonsson Patrik · August 17, 2026 · Sale6.5K @ $1,175
- Juan R. Luciano · August 17, 2026 · Grant13 @ $1,183
- J. Erik Fyrwald · August 17, 2026 · Grant8 @ $1,183
- Ralph Alvarez · August 17, 2026 · Grant10 @ $1,183
- Gabrielle Sulzberger · August 17, 2026 · Grant4 @ $1,183
- Donald A. Zakrowski · August 10, 2026 · Sale2.0K @ $1,185
- Anat Hakim · August 7, 2026 · Sale5.0K @ $1,190
- Melissa Seymour · August 1, 2026 · Option Exercise981
Institutional Ownership
March 31, 2026
- Total shares held
- 754.24M
- Total value held
- $667.52B
- Institutional holders
- 4321
- Unknown91.90M
- Unknown66.49M
- Unknown53.36M
- Unknown51.33M
- Unknown35.61M
- Unknown26.34M
- Unknown24.63M
- Unknown20.19M
- Unknown15.62M
- Unknown15.44M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.